Status:

COMPLETED

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

Lead Sponsor:

University Hospital, Gentofte, Copenhagen

Collaborating Sponsors:

University of Copenhagen

Conditions:

Glucose Metabolism Disorders

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.

Detailed Description

Aim: To evaluate the contribution of metformin-induced GLP-1 secretion on the glucose-lowering effect of metformin in patients with type 2 diabetes treated with metformin for 14 days. Furthermore, the...

Eligibility Criteria

Inclusion

  • Type 2 diabetes for at least three months (diagnosed according to the criteria of the World Health Organization (WHO)), with a HbA1c \<58 mmol/mol.
  • Caucasian ethnicity
  • Lifestyle intervention and/or metformin monotherapy
  • Normal haemoglobin
  • Age \>18 years
  • BMI \>23 kg/m2 and \<35 kg/m2
  • Informed and written consent

Exclusion

  • Liver disease
  • Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery
  • Hypo- or hyperphosphataemia
  • Reduced kidney function or nephropathy
  • Treatment with medicine that cannot be paused for 12 hours
  • Intake of antibiotics two months prior to study
  • Hypo- or hypercalcaemia
  • Hypo- and hyperthyroidism
  • Treatment with oral anticoagulants
  • Active or recent malignant disease
  • Any treatment or condition requiring acute or sub-acute medical or surgical intervention
  • Lack of effective birth control in premenopausal women
  • Positive pregnancy test on study days in premenopausal women
  • Pregnancy
  • Women who are breastfeeding
  • Any condition considered incompatible with participation by the investigators
  • If the subjects receive any antibiotic treatment while included in the study they will be excluded

Key Trial Info

Start Date :

July 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 10 2017

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT03246451

Start Date

July 1 2017

End Date

December 10 2017

Last Update

July 9 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Center for Diabetes Research

Gentofte Municipality, Copenhagen, Denmark, 2900